Baltimore-based startup Inner Logic has secured $11.5 million in seed funding to advance its simulation platform for autonomous surgical systems. The round, co-led by General Catalyst and Bison Ventures, will support the company's mission to transform how medical devices are designed, tested, and validated. Formerly known as Semaphor, Inner Logic aims to provide the essential infrastructure for the next generation of procedural medicine.
A New Paradigm for Medical Device Development
Traditional medical device development relies on a slow and costly cycle of physical prototypes, cadaver labs, and animal studies. This process offers limited scope, covering only a narrow slice of anatomical variations and potential complications. Inner Logic addresses this bottleneck by moving the exploratory work into a sophisticated virtual environment.
The company's platform enables manufacturers to test devices across thousands of virtual patients derived from real clinical and procedural data. For conventional devices like catheters, this accelerates design iteration and reduces physical testing costs. For advanced autonomous systems, it provides the large-scale training and validation necessary to prove safety and performance.
Aligning with a Shifting Regulatory Landscape
Inner Logic's emergence is timed with a significant shift in regulatory thinking from the U.S. Food and Drug Administration. Recent FDA guidance from 2023 and 2025 has established a clear pathway for using computational modeling and simulation as evidence in device submissions. This regulatory evolution is the core mechanism that underpins the company's entire business model.
This approach mirrors the evolution of the autonomous driving industry, where simulation became crucial for demonstrating system safety to regulators. Inner Logic aims to establish a similar standard, where its platform's output can serve as primary evidence to support a device's clearance. Investor Reva Nohria of General Catalyst noted this shift to in silico evidence generation is fundamental for achieving procedural autonomy.
A Founding Team Rooted in Surgical Robotics
The company is led by a team with deep expertise from Johns Hopkins University, including CEO Dr. Tito Porras, who left a neurosurgery residency to launch the venture. He is joined by CTO Dr. Mathias Unberath and Chief Robotics Officer Dr. Axel Krieger, a renowned researcher in autonomous surgery. Together, the founders hold over 40 patents and have authored more than 400 peer-reviewed publications.
The company's technology commercializes groundbreaking research from Dr. Krieger's lab, including significant milestones in autonomous surgery. His STAR robot was the first to perform laparoscopic surgery on a live animal without human guidance. This body of peer-reviewed, reproducible evidence provides a strong foundation for Inner Logic's platform and its sim-to-real transfer capabilities.
Investor Confidence and Market Momentum
Investors have expressed strong confidence in Inner Logic's vision to pioneer the next wave of surgical innovation. Caleb Appleton, a partner at co-lead investor Bison Ventures, stated that embedded intelligence will drive fundamental improvements as hardware advancements become more incremental. The funding reflects a belief that Inner Logic is positioned to lead the development of this procedural intelligence.
The investment arrives as the surgical simulation market, valued at approximately $457 million in 2024, is projected to grow significantly. This growth is fueled by demand for minimally invasive procedures and greater hospital investment in surgical AI. Inner Logic's infrastructure-focused approach is well-timed to capitalize on a market where intelligence is becoming the key competitive frontier.
With its $11.5 million in new capital, Inner Logic is poised to expand its platform and deepen its commercial partnerships with medical device manufacturers. The company's focus on simulation-first development aims to accelerate innovation, enhance patient safety, and establish a new industry standard for validating intelligent surgical systems. This funding marks a critical step toward a future where procedural outcomes are less dependent on individual surgeon skill.